Clinical trials: Viruses
HIV-1 Infection
Effect of Isotretinoin on Immune Activation Among HIV-1 Infected Subjects With Incomplete CD4+ T Cell Recovery
This phase II study was done in HIV-infected participants on antiretroviral therapy to evaluate the effects of isotretinoin (a drug that is approved for use in the treatment of severe acne) on the immune system.
- Trial name
- NCT01969058
- Testing
- Isotretinoin
- Where
- 15 sites in United States, Puerto Rico
- Volunteers
- 76 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
HIV Infection
Traditional Healer-initiated HIV Counseling and Testing in South Africa
The objective of this proposal is to conduct a pilot test of a program aimed at training traditional healers to conduct HIV testing and implementing HIV testing among people living in Bushbuckridge, South Africa.
- Trial name
- NCT05079347
- Testing
- HIV rapid test
- Where
- South Africa
- Volunteers
- 418 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Respiratory Syncytial Virus Infections
A Study to Assess Safety, Pharmacokinetics Anti-Drug Antibody and Anti-RSV Antibody After 2 Doses of Nirsevimab
The purpose of this study is to measure the safety, PK, occurrence of ADA to nirsevimab, and anti-RSV neutralizing Ab in Japanese children with certain health conditions or pre-term infants aged ≤12 months.
- Trial name
- JUBILUS (NCT06042049)
- Testing
- Nirsevimab
- Where
- 9 sites in Japan
- Volunteers
- 33 people
- Sponsor
- AstraZeneca
Alpha-1 Antitrypsin Deficiency
Safety & Efficacy Study of rAAV1-CB-hAAT for Alpha-1 Antitrypsin Deficiency
Assessment of the safety and efficacy of intramuscular (IM) administration of a recombinant adenoassociated virus (rAAV) alpha-1 antitrypsin (AAT) vector (rAAV1-CB-hAAT) in AAT-deficient adults at three dosage levels [6.0 ×…
- Trial name
- NCT01054339
- Testing
- rAAV1-CB-hAAT
- Where
- 4 sites in United States, Ireland
- Volunteers
- 9 people
- Sponsor
- Beacon Therapeutics
Idiopathic Pulmonary Fibrosis
A Pilot Trial of Herpesvirus Treatment in Idiopathic Pulmonary Fibrosis (IPF)
The investigators will conduct a single-center, prospective, randomized, placebo-controlled, double-blind pilot study of anti-herpesvirus therapy in patients with idiopathic pulmonary fibrosis (IPF).
- Trial name
- NCT02871401
- Testing
- Valganciclovir
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Vanderbilt University Medical Center
Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
Safety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy Volunteers
The purpose of this Phase 2a, randomized, blinded, placebo-controlled, multi-center study is to evaluate the safety, tolerability and immunogenicity of INO-4700 administered by intradermal (ID) injection followed by…
- Trial name
- NCT04588428
- Testing
- INO-4700, CELLECTRA™ 2000
- Where
- 6 sites in Jordan, Kenya and 1 more
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- Inovio Pharmaceuticals
Breast Cancer, Chronic Myeloproliferative Disorders
Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant
RATIONALE: Antiemetic drugs, such as aprepitant, granisetron, and dexamethasone, may help lessen or prevent nausea and vomiting in patients treated with chemotherapy.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia
- Trial name
- NCT00293384
- Testing
- Aprepitant, Cyclophosphamide, Dexamethasone
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Prone Positioning, High Flow Nasal Cannula
Early PP With HFNC Versus HFNC in COVID-19 Induced Moderate to Severe ARDS
Coronavirus disease 2019 (COVID-19) is an emerging infectious disease that was first reported in Wuhan, China, and had subsequently spread worldwide. Twenty-nine percent of COVID-19 patients may develop ARDS.
- Conditions
- Prone Positioning, High Flow Nasal Cannula, Acute Respiratory Distress Syndrome, Corona Virus Infection
- Trial name
- NCT04325906
- Testing
- high flow nasal cannula (HFNC), Prone positioning (PP)
- Where
- United States
- Volunteers
- 224 people
- Sponsor
- Rush University Medical Center
HIV/AIDS, Tuberculosis
Drinkers' Intervention to Prevent Tuberculosis (DIPT Study)
There is an urgent global need to decrease the high mortality of tuberculosis (TB) in persons with HIV as TB is the leading cause of death among persons with HIV worldwide.
- Trial name
- DIPT (NCT03492216)
- Testing
- Incentives for negative EtG test, Incentives for positive IsoScreen test
- Where
- 2 sites in Uganda
- Volunteers
- 680 people
- Sponsor
- University of California, San Francisco
Hepatitis C
An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C Virus
The purpose of this study is to assess the safety, efficacy, and pharmacokinetics in a carefully monitored cohort of pediatric subjects infected with hepatitis C virus (HCV) on a telaprevir-based regimen in Part A and with dose…
- Trial name
- NCT01701063
- Testing
- Telaprevir, Peginterferon alfa-2b, Ribavirin
- Where
- 23 sites in United States, Belgium and 4 more
- Volunteers
- 42 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Hepatitis C, HIV Coinfection
Supporting Treatment Outcomes Among PWID
The goal of this study is to improve HCV care continuum outcomes for people who inject drugs (PWID), reduce potential onward transmission to others and improve HIV outcomes among those who are HIV/HCV coinfected.
- Trial name
- STOP-C (NCT04652804)
- Testing
- Low intensity HCV treatment adherence support, Medium intensity HCV treatment adherence support, High intensity HCV treatment adherence support
- Where
- India
- Volunteers
- 3,000 people
- Sponsor
- Johns Hopkins University
COVID 19
CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION
The objective of CROWN CORONATION is the prevention of symptomatic COVID-19 by using combinations of approved and safe repurposed interventions, with complementary mechanisms of action.
- Trial name
- CROWN CORONA (NCT04333732)
- Testing
- MR or M-M-R II ® vaccine
- Where
- 17 sites in United States, Ghana and 3 more
- Volunteers
- 3,411 people
- Sponsor
- Washington University School of Medicine
Influenza
Pivotal, Multicenter, Observer-Blind, Randomized Study of Influenza A (H1N1)2009 Monovalent Subunit Vaccine With and Without Adjuvant in Children Ages 6 to <36 Months
This study will evaluate the safety and immunogenicity of different combinations of A/H1N1 2009 (swine flu) vaccine in healthy young children
- Trial name
- NCT00996307
- Testing
- MF59-eH1N1_f
- Where
- 29 sites in United States, Mexico
- Volunteers
- 654 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza
Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine for the Elderly
The objective of the study is to evaluate immunogenicity between different formulations of GSK Biologicals' investigational vaccine GSK2186877A.
- Trial name
- NCT00938392
- Testing
- GSK investigational FluNG vaccine GSK2186877A, aged lot, GSK investigational FluNG vaccine GSK2186877A, fresh lot
- Where
- 6 sites in Estonia, Slovakia
- Volunteers
- 726 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID-19
Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19
Recombinant human angotensin-converting enzyme 2 (rhACE2) as a treatment for patients with COVID-19 to block viral entry and decrease viral replication.
- Trial name
- APN01-COVID-19 (NCT04335136)
- Testing
- RhACE2 APN01, Physiological saline solution
- Where
- 22 sites in Austria, Denmark and 3 more
- Volunteers
- 185 people
- Sponsor
- Apeiron Biologics
Hepatitis, Hepatitis C, Chronic
PEG-Intron Plus Rebetol Treatment of Chronic Hepatitis C Subjects Who Failed Response to Alpha-Interferon Plus Ribavirin (Study P02370)
The objective of this study is to determine the effectiveness of PEG-Intron 1.5 ug/kg/wk plus REBETOL (ribavirin) 800-1400 mg/day in adults with chronic hepatitis C with moderate to severe liver fibrosis or cirrhosis who failed…
- Conditions
- Hepatitis, Hepatitis C, Chronic, Fibrosis, Liver Cirrhosis
- Trial name
- NCT00039871
- Testing
- PegIntron (peginterferon alfa-2b; SCH 54031), REBETOL (ribavirin; SCH 18908)
- Volunteers
- 2,333 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Myeloproliferative Disorders, Leukemia
Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
RATIONALE: Giving low doses of chemotherapy, such as busulfan and fludarabine, before a donor stem cell transplant helps stop the growth of cancer and abnormal cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00448201
- Testing
- anti-thymocyte globulin, sargramostim, therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia
Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
This randomized clinical trial is studying giving calaspargase pegol together with combination chemotherapy to see how well it works compared with giving pegaspargase together with combination chemotherapy in treating younger…
- Conditions
- Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia
- Trial name
- NCT00671034
- Testing
- Calaspargase Pegol-mknl, Cyclophosphamide, Cytarabine
- Where
- 27 sites in United States
- Volunteers
- 166 people
- Sponsor
- Children's Oncology Group
Idiopathic Parkinson's Disease
Double-Blind, Multicenter, Sham Surgery Controlled Study of CERE-120 in Subjects With Idiopathic Parkinson's Disease
The purpose of this double blind study is to determine whether CERE-120 (adeno-associated virus serotype 2 [AAV2]-neurturin [NTN]) is effective and safe in the treatment of patients with idiopathic Parkinson's Disease.
- Trial name
- NCT00400634
- Testing
- CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN])
- Where
- 9 sites in United States
- Volunteers
- 58 people
- Sponsor
- Sangamo Therapeutics
Hemorrhagic Fever, Ebola
Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo
The purpose of the study is to assess the long-term safety profile of Ad26.ZEBOV and MVA-BN-Filo in participants previously exposed to these vaccines in Phase 1, 2, or 3 clinical studies.
- Trial name
- NCT02661464
- Testing
- Ad26.ZEBOV, MVA-BN-Filo
- Where
- 16 sites in United States, Burkina Faso and 5 more
- Volunteers
- 677 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.